ArticleChest2026
Positive Airway Pressure Therapy and Health Care Resource Use in Patients With OSA and Comorbid Insomnia.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond respiratory control in COMISA: Towards precision phenotyping in PAP-based therapies.Sleep medicine reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInsomnia and OSA, together known as comorbid insomnia and OSA (COMISA), are highly prevalent sleep disorders, each of which has the potential to impair treatment efficacy for the other. RESEARCH QUESTION: Is adherence to positive airway pressure (PAP) therapy, the first-line treatment for OSA, associated with reduced health care resource use in patients with COMISA? STUDY DESIGN AND
methodsWe linked de-identified payer-sourced medical claims and objective PAP use data for patients with insomnia and newly diagnosed with OSA. Inverse probability of treatment weighting was used to create covariate-balanced groups of patients who either were adherent, intermediately adherent, or nonadherent to PAP therapy to compare rates of hospitalizations and emergency room (ER) visits. A contextual analysis was conducted among those with OSA without insomnia.
resultsFrom a sample of 27,071 patients with COMISA (average age, 53.6 years; 53% female), 72% were at least intermediately adherent to PAP over 2 years. During the first year, PAP adherence was associated significantly with fewer ER visits (mean [SD]: adherent, 0.50 [1.39] vs intermediate, 0.59 [1.36] [P < .001]; vs nonadherent, 0.68 [1.74] [P < .001]) and all-cause hospitalizations (mean [SD]: adherent, 0.10 [0.53] vs intermediate, 0.15 [0.60] [P < .001]; vs nonadherent, 0.14 [0.57] [P < .001]). Results were similar in the second year of PAP use. When viewed in the context of patients with OSA without insomnia, patients with COMISA showed lower PAP use and higher rates of resource use both before and after the index date, but showed similar relative reductions in ER visits and hospitalizations with PAP adherence.
interpretationThese results provide additional evidence from a large, diverse sample to support the treatment of OSA in patients with COMISA and encourage development of COMISA-specific strategies to improve acceptance of PAP therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.